-
11.发明申请Genetic modification of liver cells to enhance metabolic and physiological efficacy 审中-公开肝细胞的遗传修饰以增强代谢和生理功效公开(公告)号：US20070105224A1
公开(公告)日：2007-05-10
申请号：US11267419
申请日：2005-11-07
申请人： Chin-Yu Lin , See-Chang Huang , Chun-Min Liu
发明人： Chin-Yu Lin , See-Chang Huang , Chun-Min Liu
IPC分类号： C12N15/867 , C12N5/08
CPC分类号： C12N15/86 , A61K38/1709 , A61K48/005 , C12N2740/13043
摘要： Retroviral vectors containing hepatic nuclear factor 1 or hepatic nuclear factor 4α, and cells comprising the same are provided.
摘要翻译： 提供含有肝脏核因子1或肝脏核因子4alpha的逆转录病毒载体，以及包含其的细胞。
-
公开(公告)号：US07157571B2
公开(公告)日：2007-01-02
申请号：US11030110
申请日：2005-01-07
申请人： Mei-Chih Wang , Chin-Yu Lin , Hui-Ti Lin , Mei-Hwei Fan-Chiang
发明人： Mei-Chih Wang , Chin-Yu Lin , Hui-Ti Lin , Mei-Hwei Fan-Chiang
CPC分类号： G01N33/5067 , C12N15/85 , C12N2830/008 , C12N2830/85 , G01N2800/52
摘要： The present invention relates to a chimeric regulatory sequence with hepatoma cell specificity. The chimeric regulatory sequence includes a proximal regulatory sequence and a distal enhancer of 5′ flanking region of human α-fetoprotein (AFP) gene.
摘要翻译： 本发明涉及具有肝癌细胞特异性的嵌合调节序列。 嵌合调节序列包括近端调节序列和人甲胎蛋白（AFP）基因的5'侧翼区的远端增强子。
-
公开(公告)号：US20110246399A1
公开(公告)日：2011-10-06
申请号：US13151142
申请日：2011-06-01
IPC分类号： G06Q90/00
CPC分类号： C12Q1/6886 , A61K39/39558 , B65B61/20 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57407 , G01N33/57415 , G01N33/57423 , G01N33/57434 , G01N33/57449 , G06Q99/00 , A61K2300/00
摘要： The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
-
公开(公告)号：US07935527B2
公开(公告)日：2011-05-03
申请号：US11008929
申请日：2004-12-13
申请人： Mei-Chih Wang , Mei-Hwei Fan-Chiang , Hui-Ti Lin , Chin-Yu Lin
发明人： Mei-Chih Wang , Mei-Hwei Fan-Chiang , Hui-Ti Lin , Chin-Yu Lin
IPC分类号： C12N5/00
CPC分类号： C12N5/0606 , C12N2501/70 , C12N2502/13 , C12N2502/1323 , C12N2510/00 , C12N2533/50 , C12N2533/52 , C12N2533/54
摘要： The present invention discloses a method for improving growth and survival of single human embryonic stem cells. The method includes the step of obtaining a single undifferentiated HES cell; mixing the single undifferentiated cell with an extracellular matrix (ECM) to encompass the cell; and inoculating the mixture onto feeder cells with a nutrient medium in a growth environment. Therefore the single cells can survive, proliferate and grow in vitro.
摘要翻译： 本发明公开了一种改善单人胚胎干细胞生长和存活的方法。 该方法包括获得单个未分化HES细胞的步骤; 将单个未分化细胞与细胞外基质（ECM）混合以包围细胞; 并在生长环境中用营养培养基将混合物接种到饲养细胞上。 因此，单细胞可以在体外存活，增殖和生长。
-
公开(公告)号：US20100008975A1
公开(公告)日：2010-01-14
申请号：US12074229
申请日：2008-03-01
IPC分类号： A61K9/127 , A61K39/395 , G01N33/566 , A61P35/00
CPC分类号： C12Q1/6886 , A61K39/39558 , B65B61/20 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57407 , G01N33/57415 , G01N33/57423 , G01N33/57434 , G01N33/57449 , G06Q99/00 , A61K2300/00
摘要： The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
摘要翻译： 本申请描述了使用低HER3作为治疗患有HER抑制剂的患者的选择标准，例如珀妥珠单抗。 它还描述了使用高HER2：HER3比例作为治疗癌症患者（如卵巢癌患者）的选择标准，其具有HER抑制剂如妥他珠单抗。 此外，本申请描述了使用高HER3作为治疗癌症患者与化疗剂例如吉西他滨的选择标准。
-
-
-
-
搜索结果
15 条记录 (耗时 0.036 秒)
